Hypogonadism in men with chronic obstructive pulmonary disease: Prevalence and quality of life

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 7, 2005, Pages 728-733

  Laghi, Franco ^a   Antonescu Turcu, Andreea ^b   Collins, Eileen ^b   Segal, Jeremy ^b   Tobin, Damien E ^b   Jubran, Amal ^b   Tobin, Martin J ^b  

^a Rehabilitation Research and Development Section   (United States)

^b NONE

Author keywords

Aging; Androgens; Exercise tolerance; Health status; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; AGING; ANDROGEN DEFICIENCY; ARTICLE; BLOOD SAMPLING; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; EXERCISE; EXERCISE TOLERANCE; HEALTH STATUS; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; COHORT STUDIES; COMORBIDITY; EXERCISE TOLERANCE; HUMANS; HYPOGONADISM; MALE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 16344387528     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200501-037OC     Document Type: Article

References (57)

1. National Heart, Lung, and Blood Institute. Data fact sheet. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD. Available from: http://www.nhlbi.nih.gov/ health/public/lung/other/copd_fact.pdf (accessed October 26, 2004).
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
3. Nierman DM, Mechanick JI. Hypotestosteronemia in chronically critically ill men. Crit Care Med 1999;27;2418-2421.
4. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991;44:671-684.
5. Leifke E, Gorenoi V, Wichers C, Von Zur MA, Von Buren E, Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf) 2000; 53:689-695.
6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
7. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
8. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289.
9. Moy ML, Ingenito EP, Mentzer SJ, Evans RB, Reilly JJ Jr. Health-related quality of life improves following pulmonary rehabilitation and lung volume reduction surgery. Chest 1999;115:383-389.
10. Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation [abstract]. Am J Respir Crit Care Med 1996;153:A128.
11. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM, Magnussen H, Nieschlag E. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998;11:41-45.
12. Gosney JR. Atrophy of Leydig cells in the testes of men with longstanding chronic bronchitis and emphysema. Thorax 1987;42:615-619.
13. Aasebo U, Gyltnes A, Bremnes RM, Aakvaag A, Slordal L. Reversal of sexual impotence in male patients with chronic obstructive pulmonary disease and hypoxemia with long-term oxygen therapy. J Steroid Biochem Mol Biol 1993;46:799-803.
14. Morley JE, Perry HM III. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol 2003;85:367-373.
15. Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bammert C, Tobin MJ. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;171:598-605.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145: 1321-1327.
17. Larson JL, Covey MK, Wirtz SE, Berry JK, Alex CG, Langbein WE, Edwards L. Cycle ergometer and inspiratory muscle training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160: 500-507.
18. Segal JM, Antonescu-Turcu A, Tobin DE, Collins E, Bhorade S, Laghi F. Impact of hypogonadism on physical and mental health in patients with chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med 2001;163:A912.
19. Antonescu-Turcu A, Segal JM, Tobin DE, Malik I, Langbein WE, Laghi F. Does hypogonadism impact respiratory symptoms and exercise per formance in patients with chronic obstructive pulmonary disease [abstract]? Am J Respir Crit Care Med 2001;163:A911.
20. Kazis LE, Ren XS, Lee A, Skinner K, Rogers W, Clark J, Miller DR. Health status in VA patients: results from the Veterans Health Study. Am J Med Qual 1999;14:28-38.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992: 30:473-483.
22. Perlin J, Kazis LE, Skinner KM, Ren XS, Lee A, Rogers W, Spiro A III, Selim A, Miller D. Health status and outcomes of veterans: physical and mental component summary scores Veterans SF-36. 1999 large health survey of veteran enrollees. Executive report. Washington, DC: Office of Quality and Performance. Department of Veterans Affairs; 2000.
23. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 1982;284:1607-1608.
24. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, Plaza V, Prieto L, Anto JM. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127:1072-1079.
25. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, Rengo F. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003;22:444-449.
26. Ferrer M, Villasante C, Alonso J, Sobradillo V, Gabriel R, Vilagut G, Masa JF, Viejo JL, Jimenez-Ruiz CA, Miravitlles M. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002;19:405-413.
27. Selim AJ, Ren XS, Fincke G, Rogers W, Lee A, Kazis L. A symptom-based measure of the severity of chronic lung disease: results from the Veterans Health Study. Chest 1997;111:1607-1614.
28. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995;107:1585-1589.
29. Sant'Anna CA, Stelmach R, Zanetti Feltrin MI, Filho WJ, Chiba T, Cukier A. Evaluation of health-related quality of life in low-income patients with COPD receiving long-term oxygen therapy. Chest 2003; 123:136-141.
30. Lindholm E, Brevinge H, Bergh CH, Korner U, Lundholm K. Relationships between self-reported health related quality of life and measures of standardized exercise capacity and metabolic efficiency in a middle-aged and aged healthy population. Qual Life Res 2003;12:575-582.
31. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306:1437-1440.
32. Kazis LE, Lee AF, Spiro A III, Miller DR, Rogers W, Ren XS, Zhang M. HOS/VA (Veterans Administration) comparison project part 2: test of reliability and validity at the scale level for Medicare HOS SF-36 (R) and VA Veterans SF-36. Available from: http://www.cms.hhs.gov/surveys/hos/download/ HOS_VA_Comparison_Project_Part2.pdf (Accessed January 14, 2004).
33. Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002;51:554-559.
34. Debigare R, Marquis K, Cote CH, Tremblay RR, Michaud A, LeBlanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-89.
35. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-1025.
36. Semple PD, Beastall GH, Watson WS, Hume R. Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci (Lond) 1980;58:105-106.
37. Strain GW, Zumoff B, Miller LK, Rosner W. Sex difference in the effect of obesity on 24-hour mean serum gonadotropin levels. Horm Metab Res 2003;35:362-366.
38. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104: 648-651.
39. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996;20:291-302.
40. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
41. Jockenhovel F, Blum WF, Vogel E, Englaro P, Muller-Wieland D, Reinwein D, Rascher W, Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997;82:2510-2513.
42. Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y, et al. Human obese gene expression: adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995;44:855-858.
43. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-549.
44. Mealy K, Robinson B, Millette CF, Majzoub J, Wilmore DW. The testicular effects of tumor necrosis factor. Ann Surg 1990;211:470-475.
45. Cover PO, Baanah-Jones F, John CD, Buckingham JC. Annexin 1 (lipocortin 1) mimics inhibitory effects of glucocorticoids on testosterone secretion and enhances effects of interleukin-1beta. Endocrine 2002; 18:33-39.
46. Gao HB, Tong MH, Hu YQ, You HY, Guo QS, Ge RS, Hardy MP. Mechanisms of glucocorticoid-induced Leydig cell apoptosis. Mol Cell Endocrinol 2003;199:153-163.
47. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, Khalaf A, Marrades RM, Monso E, Serra-Batlles J, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-685.
48. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167:544-549.
49. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384-1387.
50. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573-577.
51. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, Weinstein MC. Performance of a five-item mental health screening test. Med Care 1991;29:169-176.
52. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
53. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997;52:67-71.
54. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:3435-3448.
55. Bagatell CJ, Bremner WJ. Androgens in men-uses and abuses. N Engl J Med 1996;334:707-714.
56. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003;88:1478-1485.
57. Snyder PJ. Hypogonadism in elderly men-what to do until the evidence comes. N Engl J Med 2004;350:440-442.